-
1
-
2دورية أكاديمية
المؤلفون: Ren, WC, Ye, XF, Su, H, Li, W, Liu, DB, Pirmoradian, M, Wang, XH, Zhang, B, Zhang, Q, Chen, LY, Nie, M, Liu, Y, Meng, B, Huang, HQ, Jiang, WQ, Zeng, YX, Li, WY, Wu, K, Hou, Y, Wiman, KG, Li, ZM, Zhang, HL, Peng, RJ, Zhu, SD, Pan-Hammarstrom, Q
المصدر: Blood. 131(24):2670-2681
مصطلحات موضوعية: Medicin och hälsovetenskap
-
3دورية أكاديمية
المؤلفون: Nie, M, Ren, WC, Ye, XF, Berglund, M, Wang, XH, Fjorden, K, Du, LK, Giannoula, Y, Lei, DX, Su, WJ, Li, W, Liu, DB, Linderoth, J, Jiang, CY, Bao, HJ, Jiang, WQ, Huang, HQ, Hou, Y, Zhu, SD, Enblad, G, Jerkeman, M, Wu, K, Zhang, HL, Amini, RM, Li, ZM, Pan-Hammarstrom, Q
المصدر: Clinical and translational medicine. 12(12):e1118
مصطلحات موضوعية: Medicin och hälsovetenskap
-
4دورية أكاديمية
المؤلفون: Wang, T, Tan, JY, Liu, XL, Zheng, SL, Zhao, I, Eliseeva, S, Polotan, MJ, Cheng, HL, Huang, HQ
المساهمون: School of Nursing
الوصف: 202212 bckw ; Version of Record ; Published ; CC
العلاقة: http://hdl.handle.net/10397/96482Test; 12; 2-s2.0-85123667959; e054597; OA_Scopus/WOS
-
5دورية أكاديمية
المؤلفون: Gershenson, DM, Miller, A, Brady, WE, Paul, J, Carty, K, Rodgers, W, Millan, D, Coleman, RL, Moore, KN, Banerjee, S, Connolly, K, Secord, AA, O'Malley, DM, Dorigo, O, Gaillard, S, Gabra, H, Slomovitz, B, Hanjani, P, Farley, J, Churchman, M, Ewing, A, Hollis, RL, Herrington, CS, Huang, HQ, Wenzel, L, Gourley, C
المساهمون: Banerjee, Susana
مصطلحات موضوعية: Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Ovarian Epithelial, Female, Humans, MAP Kinase Kinase 1, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Ovarian Neoplasms, Paclitaxel, Progression-Free Survival, Pyridones, Pyrimidinones, Standard of Care, Treatment Outcome, United Kingdom, United States
جغرافية الموضوع: England
الوصف: BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma. METHODS: This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m2 by body surface area once every 4 weeks; intravenous topotecan 4 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, ...
وصف الملف: Print; 553; application/pdf
العلاقة: S0140-6736(21)02175-9; The Lancet, 2022, 399 (10324), pp. 541 - 553; https://repository.icr.ac.uk/handle/internal/5220Test
الإتاحة: https://doi.org/10.1016/S0140-6736Test(21)02175-9
https://repository.icr.ac.uk/handle/internal/5220Test -
6دورية أكاديمية
المؤلفون: Penson, RT, Huang, HQ, Wenzel, LB, Monk, BJ, Stockman, S, Long, HJ, Ramondetta, LM, Landrum, LM, Oaknin, A, Reid, TJA, Leitao, MM, Method, M, Michael, H, Tewari, KS
المصدر: The Lancet Oncology. 16(3)
مصطلحات موضوعية: Oncology and Carcinogenesis, Oncology & Carcinogenesis
الوصف: Background: GOG 240 was a practice-changing randomised phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall and progression-free survival, and the proportion of patients achieving an overall objective response, compared with chemotherapy alone. In this study, we aimed to analyse patient-reported outcomes in GOG 240. Methods: Eligible adult participants (aged ≥18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease and GOG performance status of 0-1. Participants were randomly assigned by web-based permuted block randomisation (block size 4) in a 1:1:1:1 ratio to the four treatment groups: cisplatin (50 mg/m2 intravenously on day 1 or 2 of the treatment cycle) and paclitaxel (135 mg/m2 intravenously over 24 h or 175 mg/m2 intravenously over 3 h on day 1), with or without bevacizumab (15 mg/kg intravenously on day 1 or 2), or paclitaxel (175 mg/m2 over 3 h on day 1) and topotecan (0·75 mg/m2 for 30 min on days 1-3) with or without bevacizumab (15 mg/kg intravenously on day 1). Treatment assignment was concealed at randomisation (everyone was masked to treatment assignment, achieved by the use of a computer encrypted numbering system at the National Cancer Institute) and became open-label when each patient was registered to the trial. Treatment cycles were repeated every 21 days until disease progression or unacceptable toxicity, whichever occurred first. The coprimary endpoints of the trial were overall survival and safety; the primary quality-of-life endpoint was the score on the Functional Assessment of Cancer Therapy-Cervix Trial Outcome Index (FACT-Cx TOI). For our analysis of patient-reported outcomes, participants were assessed before treatment cycles 1, 2, and 5, and at 6 and 9 months after the start of cycle 1, with the FACT-Cx TOI, items from the FACT-GOG-Neurotoxicity subscale, and a worst pain item from the Brief Pain Inventory. All patients who completed baseline quality-of-life assessments and at least one further follow-up assessment were evaluable for quality-of-life outcomes. This study is registered with ClinicalTrials.gov, number NCT00803062. Findings: Between April 6, 2009, and Jan 3, 2012, a total of 452 patients were enrolled in the trial, of whom 390 completed baseline quality-of-life assessment and at least one further assessment and were therefore evaluable for quality-of-life outcomes. In these patients, patient-reported outcome completion declined from 426 (94%) of 452 (at baseline) to 193 (63%) of 307 (9 months post-cycle 1), but completion rates did not differ significantly between treatment regimens (p=0·78). The baseline FACT-Cx TOI scores did not differ significantly between patients who received bevacizumab versus those who did not (p=0·27). Compared with patients who received chemotherapy alone, patients who received chemotherapy plus bevacizumab reported FACT-Cx TOI scores that were an average of 1·2 points lower (98·75% CI -4·1 to 1·7; p=0·30). Interpretation: Improvements in overall survival and progression-free survival attributed to the incorporation of bevacizumab into the treatment of advanced cervical cancer were not accompanied by any significant deterioration in health-related quality of life. Patients responding to anti-angiogenesis therapy who maintain an acceptable quality of life could be suitable at progression for treatment with other novel therapies that might confer additional benefit. Funding: National Institutes of Health.
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/9mm45442Test
-
7دورية أكاديمية
المؤلفون: Wang, T, Molassiotis, A, Chung, BPM, Zheng, SL, Huang, HQ, Tan, JYB
المساهمون: School of Nursing
مصطلحات موضوعية: Cancer survivors, Caregivers, China, Information needs
الوصف: 202110 bcvc ; Version of Record ; Published ; CC
العلاقة: http://hdl.handle.net/10397/91329Test; 20; 2-s2.0-85107548192; 83; OA_Scopus/WOS
-
8دورية أكاديمية
المؤلفون: Gershenson, DM, Miller, A, Brady, WE, Paul, J, Carty, K, Rodgers, W, Millan, D, Coleman, RL, Moore, KN, Banerjee, S, Connolly, K, Secord, AA, O'Malley, DM, Dorigo, O, Gaillard, S, Gabra, H, Slomovitz, B, Hanjani, P, Farley, J, Churchman, M, Ewing, A, Hollis, RL, Herrington, CS, Huang, HQ, Wenzel, L, Gourley, C
المصدر: 553 ; 541
مصطلحات موضوعية: 11 Medical and Health Sciences, General & Internal Medicine
جغرافية الموضوع: England
الوصف: BACKGROUND: Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade serous carcinoma. We compared the MEK inhibitor trametinib to physician's choice standard of care in patients with recurrent low-grade serous carcinoma. METHODS: This international, randomised, open-label, multicentre, phase 2/3 trial was done at 84 hospitals in the USA and UK. Eligible patients were aged 18 years or older with recurrent low-grade serous carcinoma and measurable disease, as defined by Response Evaluation Criteria In Solid Tumors version 1.1, had received at least one platinum-based regimen, but not all five standard-of-care drugs, and had received an unlimited number of previous regimens. Patients with serous borderline tumours or tumours containing low-grade serous and high-grade serous carcinoma were excluded. Eligible patients were randomly assigned (1:1) to receive either oral trametinib 2 mg once daily (trametinib group) or one of five standard-of-care treatment options (standard-of-care group): intravenous paclitaxel 80 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m2 by body surface area once every 4 weeks; intravenous topotecan 4 mg/m2 by body surface area on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. Randomisation was stratified by geographical region (USA or UK), number of previous regimens (1, 2, or ≥3), performance status (0 or 1), and planned standard-of-care regimen. The primary endpoint was investigator-assessed progression-free survival while receiving randomised therapy, as assessed by imaging at baseline, once every 8 weeks for 15 months, and then once every 3 months thereafter, in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02101788, ...
العلاقة: The Lancet; http://hdl.handle.net/10044/1/95217Test
الإتاحة: https://doi.org/10.1016/S0140-6736Test(21)02175-9
http://hdl.handle.net/10044/1/95217Test -
9دورية أكاديمية
المؤلفون: Jin J, Okamoto R, Yoon SS, Shih LY, Zhu J, Liu T, Hong XN, Pei L, Rooney B, van de Velde H, Huang HQ
المصدر: OncoTargets and Therapy, Vol Volume 11, Pp 3869-3882 (2018)
مصطلحات موضوعية: Mantle cell lymphoma, bortezomib, VR-CAP, R-CHOP, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Jie Jin,1,2 Rumiko Okamoto,3 Sung-Soo Yoon,4 Lee-Yung Shih,5 Jun Zhu,6 Ting Liu,7 Xiaonan Hong,8 Lixia Pei,9 Brendan Rooney,10 Helgi van de Velde,11 Huiqiang Huang12 1Department of Hematology, The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang, China; 2Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, China; 3Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; 5Division of Hematology–Oncology, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taoyuan, Taiwan; 6Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China; 7Division of Hematology, Department of Internal Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China; 8Lymphoma and GI Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; 9Janssen Research & Development, LLC, Raritan, NJ, USA; 10Janssen Research & Development, High Wycombe, Buckinghamshire, UK; 11Oncology Clinical Research, Millennium Pharmaceuticals, Inc., Boston, MA, USA; 12Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China Introduction: This subgroup analysis of the LYM-3002 Phase III study (NCT00722137) investigated whether substituting bortezomib for vincristine in frontline R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy could improve outcomes in East Asian patients with newly diagnosed mantle-cell lymphoma (MCL). Materials and methods: A total of 121 East Asian patients from China, Taiwan, Japan, and the Republic of Korea with stage II–IV MCL who were ineligible or not considered for stem-cell transplantation were enrolled to six to eight 21-day cycles of R-CHOP or VR-CAP (R-CHOP with bortezomib replacing vincristine). Results: The primary end point was progression-free survival. After a median follow-up of 42.4 months, median progression-free survival in East Asian patients was 13.9 (R-CHOP) versus 28.6 (VR-CAP) months (HR 0.7, P=0.157; 43% improvement with VR-CAP). Secondary end points (R-CHOP vs VR-CAP), including complete response rate (47% vs 63%), duration of complete response (median 16.6 vs 46.7 months), and treatment-free interval (median 21 vs 46.5 months), were improved with VR-CAP. VR-CAP was associated with increased but manageable toxicity. The most frequent adverse events were hematologic toxicities. Conclusion: VR-CAP was effective in East Asian patients with newly diagnosed MCL, and could be considered for patients in whom stem-cell transplantation is not an option. Keywords: mantle-cell lymphoma, bortezomib, VR-CAP, R-CHOP
وصف الملف: electronic resource
-
10دورية أكاديمية
المصدر: OncoTargets and Therapy, Vol Volume 9, Pp 5875-5881 (2016)
مصطلحات موضوعية: extranodal NK/T-cell lymphoma, radiotherapy, prognosis, asparaginase, radiation-related toxicity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Liang Wang,1,2,* Xi-wen Bi,1,3,* Zhong-jun Xia,1,2 Hui-qiang Huang,1,3 Wen-qi Jiang,1,3 Yu-jing Zhang1,4 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 2Department of Hematologic Oncology, 3Department of Medical Oncology, 4Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China *These authors contributed equally to this work Abstract: Previous studies have found that radiotherapy (RT) dose less than 50 Gy resulted in inferior outcomes for early stage extranodal NK/T-cell lymphoma (ENKTL). Nowadays, induction chemotherapy (CT) followed by RT consolidation is often used. For patients who get complete response (CR) after CT, whether RT dose can be safely reduced or not remains unknown. This retrospective study compared the survival outcomes between patients who received higher dose (>50 Gy) and lower dose (≤50 Gy) RT after CR was attained by CT. One hundred and forty four patients of early stage ENKTL got CR after induction CT and received RT consolidation. Thirty-one patients received lower dose RT (median 46 Gy, range, 36–50 Gy), and 113 patients received higher dose RT (median 56 Gy, range, 52–66 Gy). In univariate survival analysis, age >60, local tumor invasion, and non-asparaginase-based CT were associated with inferior progression-free survival (PFS) and overall survival (OS). However, there were no differences in PFS and OS between patients treated with higher and lower dose RT, which was confirmed in the multivariate survival analysis. Furthermore, reduced dose RT did not affect local control rate. Most common RT-related side effects were grade 1/2 mucositis and dermatitis, and the incidence rate of grade 3 mucositis or dermatitis was lower in patients treated with reduced dose RT (9.7% vs 15.0% for mucositis, and 6.5% vs 17.7% for dermatitis). In conclusion, this study found that RT dose could be safely reduced without compromising survival outcomes and further improved RT-related side effects. Prospective randomized controlled trials are warranted to validate our findings. Keywords: extranodal NK/T-cell lymphoma, radiotherapy, prognosis, asparaginase, radiation-related toxicity
وصف الملف: electronic resource
النص الكامل